Document is current
Any future updates will be listed below
-
Authors
Smith, Autumn
Wechsler, Michael E.
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 15 April 2025
Accepted: 7 October 2025
First Online: 1 November 2025
Declarations
:
: Michael E Wechsler has received consulting, advisory or speaking honoraria from the following: Amgen, Areteia Therapeutics, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Celldex, Cellergy Pharma, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GlaxoSmithKline, Incyte, Kinaset, Merck, Novartis, Om Pharma, Overtone Therapeutics/Foresite Labs, Phylaxis, Pulmatrix, Rapt Therapeutics, Regeneron, Restorbio, Roche/Genentech, Sanofi/Genzyme, Sentien, Sound Biologics, Tetherex Pharmaceuticals, Teva, Upstream Bio and Verona Pharma. Autumn Smith has nothing to disclose.
: This podcast of a patient-physician discussion does not require any ethical approval.
